(97 days)
No
The summary describes a PC-based processing system for interpreting OCT signals but does not mention AI, ML, or any related concepts. The focus is on OCT-assisted orientation and imaging as an adjunct to fluoroscopy.
No.
The device is intended to assist in guidewire placement and provide imaging for diagnosis, not for therapeutic treatment itself.
Yes
The device provides images of vessel lumen and wall structures to facilitate guidewire placement, which is a form of diagnosis or assessment of the anatomical state. Furthermore, it is described as an "Imaging System."
No
The device description clearly states that the Ocelot System consists of hardware components including the Ocelot Catheter, the Lightbox Imaging Console (which includes a cart, monitors, PC, isolation transformer, and OCT system), and the Umbilical. While it includes software for processing, it is not solely software.
Based on the provided text, the Ocelot System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use clearly states that the system is used to facilitate the intraluminal placement of guidewires within the peripheral vasculature using OCT-assisted orientation and imaging. This is a procedure performed within the body (in vivo), not on samples taken from the body (in vitro).
- Device Description: The device description details a catheter inserted into the body, an imaging console that processes signals from within the body, and an umbilical connecting them. This aligns with an in vivo imaging and procedural guidance system.
- Input Imaging Modality: Optical Coherence Tomography (OCT) in this context is used for imaging structures within the blood vessels.
- Anatomical Site: The peripheral vasculature is a location within the living body.
IVD devices are used to examine specimens derived from the human body (such as blood, urine, tissue) to provide information for diagnosis, monitoring, or screening. The Ocelot System does not perform this function. It is an imaging and guidance system used during a medical procedure performed directly on the patient.
N/A
Intended Use / Indications for Use
The Ocelot System is intended to facilitate the intraluminal placement of conventional guidewires beyond stenotic lesions (including sub and chronic total occlusions) in the peripheral vasculature prior to further percutaneous intervention using OCT-assisted orientation and imaging. The system is an adjunct to fluoroscopy by providing images of vessel lumen and wall structures. The Ocelot System is contraindicated for use in the iliac, coronary, cerebral, renal or carotid vasculature.
Product codes (comma separated list FDA assigned to the subject device)
PDU, NQQ
Device Description
The Ocelot System consists of the Ocelot Catheter, the Lightbox Imaging Console, and the Umbilical. Unless otherwise specified, the terms "Ocelot: System" and "Ocelot Catheter" are inclusive of all Ocelot Catheters in the Ocelot Catheter family. The Ocelot Catheter is an over-the-wire, sterile, single-use device that is compatible with a 0.014" guidewire. The Ocelot Catheter incorporates an optical fiber used to facilitate Optical Coherence Tomography (OCT)-assisted orientation and imaging as an adjunct to fluoroscopy. The Lightbox Imaging Console is an optical transceiver, transmitting light to the intraluminal environment through the optical fiber on the Ocelot Catheter and receiving and interpreting the signal from the tissue using a PC-based processing system. The Lightbox Imaging Console consists of a cart with two monitors, a PC, an isolation transformer, and the OCT system. The Umbilical is a 3-meter long optical and electrical extension cable that connects the Ocelot Catheter and the Lightbox Imaging Console. The Umbilical is reusable, nonsterile, and is intended for use outside of the sterile field.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Optical Coherence Tomography (OCT), fluoroscopy
Anatomical Site
peripheral vasculature (contraindicated for use in the iliac, coronary, cerebral, renal or carotid vasculature)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification and validation testing has been completed for the Ocelot System. Validation testing included the use of the predicate device, the C7 XR Imaging System™ with the C7 Dragonfly™ Imaging Catheter (K093857). The completed testing results demonstrate that the Ocelot System is substantially equivalent to the predicate device, C7 XR Imaging System™ with the C7 Dragonfly™ Imaging Catheter (K093857) with respect to imaging of vessel lumen and wall structures. The system specifications and technological characteristics for the subject device and predicate device also demonstrate substantial equivalence with respect to OCT imaging system technology and imaging specifications.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.1250 Percutaneous catheter.
(a)
Identification. A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.(b)
Classification. Class II (performance standards).
0
AVINGER, INC.
,
MAY 0 1 2014
OCELOT SYSTEM 510(k) PREMARKET NOTIFICATION
4.0 510(K) Summary
510(k) Notification K__K140185
GENERAL INFORMATION
Applicant:
Avinger, Inc. 400 Chesapeake Drive Redwood City, CA 94063 U.S.A. Phone: 650-241-7900 Fax: 650-241-7901
Contact Person:
Sherry Kim Sr. Regulatory Affairs Specialist Avinger, Inc. Phone: 650-241-7004 Fax: 650-241-7901
Date Prepared:
January 23, 2014
DEVICE INFORMATION
Trade Name:
Ocelot System, Ocelot PIXL Catheter
Generic/Common Name:
Percutaneous Catheter
Classification:
21 CFR§870.1250, Percutaneous Catheter, Class II 21 CFR§892.1560, Ultrasonic Pulsed Echo Imaging System, Class II
Product Codes:
PDU, NQQ
1
ﺎﺋﻴﺔ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ
PREDICATE DEVICES
- Avinger Ocelot System (K122380) / Ocelot PIXL Catheter (K123532) .
- C7 XR Imaging System™ with the C7 Dragonfly™ Imaging Catheter . (K093857)
DEVICE DESCRIPTION
The Ocelot System consists of the Ocelot Catheter, the Lightbox Imaging Console, and the Umbilical. Unless otherwise specified, the terms "Ocelot: System" and "Ocelot Catheter" are inclusive of all Ocelot Catheters in the Ocelot Catheter family. The Ocelot Catheter is an over-the-wire, sterile, single-use device that is compatible with a 0.014" guidewire. The Ocelot Catheter incorporates an optical fiber used to facilitate Optical Coherence Tomography (OCT)-assisted orientation and imaging as an adjunct to fluoroscopy. The Lightbox Imaging Console is an optical transceiver, transmitting light to the intraluminal environment through the optical fiber on the Ocelot Catheter and receiving and interpreting the signal from the tissue using a PC-based processing system. The Lightbox Imaging Console consists of a cart with two monitors, a PC, an isolation transformer, and the OCT system. The Umbilical is a 3-meter long optical and electrical extension cable that connects the Ocelot Catheter and the Lightbox Imaging Console. The Umbilical is reusable, nonsterile, and is intended for use outside of the sterile field.
PROPOSED INDICATIONS FOR USE
The Ocelot System is intended to facilitate the intraluminal placement of conventional guidewires beyond stenotic lesions (including sub and chronic total occlusions) in the peripheral vasculature prior to further percutaneous intervention using OCT-assisted orientation and imaging. The system is an adjunct to fluoroscopy by providing images of vessel lumen and wall structures. The Ocelot System is contraindicated for use in the iliac, coronary, cerebral, renal or carotid vasculature.
SUBSTANTIAL EQUIVALENCE
Predicate device: Ocelot System (K122380) / Ocelot PIXL Catheter (K123532) There are no differences in the device design and technological characteristics between the Ocelot System presented in this submission and the predicate Ocelot System and Ocelot PIXL Catheter cleared under K122380 and K123532, respectively. The Ocelot System's Indications For Use cleared under K122380 and K123532 are being revised to include imaging of vessel lumen and wall structures.
Predicate device: C7 XR Imaging System™ with the C7 Dragonfly™ Imaging Catheter (K093857)
2
AVINGER, INC.
K140185
Verification and validation testing has been completed for the Ocelot System. Validation testing included the use of the predicate device, the C7 XR Imaging System™ with the C7 Dragonfly™ Imaging Catheter (K093857). The completed testing results demonstrate that the Ocelot System is substantially equivalent to the predicate device, C7 XR Imaging System™ with the C7 Dragonfly™ Imaging Catheter (K093857) with respect to imaging of vessel lumen and wall structures. The system specifications and technological characteristics for the subject device and predicate device also demonstrate substantial equivalence with respect to OCT imaging system technology and imaging specifications.
NONCLINICAL TESTING IN SUPPORT OF SUBSTANTIAL EQUIVALENCE DETERMINATION
All necessary performance testing was conducted on the Ocelot System to support a determination of substantial equivalence to the predicate devices. The non-clinical, bench testing provided in this submission includes:
- Design verification and bench validation studies .
- Packaging and shelf-life .
- . Software verification and validation
- Electrical safety, electromagnetic compatibility, and laser safety testing .
The non-clinical, bench testing conducted on the Ocelot System provided in the prior K122380 and K123532 submissions and still applicable to the current Ocelot System included:
- . Biocompatibility
- In-vivo animal validation study .
- Sterilization .
The collective results of the non-clinical testing demonstrate that the Ocelot System meets the established specifications necessary for consistent performance for its intended use. .
CLINICAL TESTING IN SUPPORT OF SUBSTANTIAL EQUIVALENCE DETERMINATION
Clinical testing results to demonstrate safety and effectiveness of the Ocelot System were included in the prior K122380 submission. No new clinical testing is included in this 510(k) submission.
CONCLUSION
As demonstrated in the testing summaries, no new issues of safety or effectiveness are raised in this submission and the Ocelot System is substantially equivalent to the predicate devices listed above.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
May 1, 2014
Avinger Inc Sherry Kim Sr. Regulatory Affairs Specialist 400 Chesapeake Drive Redwood City, CA 94063
Re: K140185
Trade/Device Name: Ocelot System: Ocelot Catheter, Ocelot PIXL Catheter, & Light Box Console
Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: PDU/NQQ Dated: March 27, 2014 Received: March 28, 2014
Dear Ms. Sherry Kim:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
Image /page/3/Picture/12 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the logo is an abstract symbol that resembles an eagle or a bird in flight.
4
Page 2 - Ms. Sherry Kim
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
forBram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Avinger, Inc.
Ocelot System 510(k) PREMARKET NOTIFICATION
3.0 INDICATIONS FOR USE STATEMENT
K140185 510(k) Number (if known): _
Device Name: Ocelot System
Indications For Use:
The Ocelot System is intended to facilitate the intraluminal placement of conventional guidewires beyond stenotic lesions (including sub and chronic total occlusions) in the peripheral vasculature prior to further percutaneous intervention using OCT-assisted orientation and imaging. The system is an adjunct to fluoroscopy by providing images of vessel lumen and wall structures. The Ocelot System is contraindicated for use in the iliac, coronary, cerebral, renal or carotid vasculature.
Prescription Use _____________________________________________________________________________________________________________________________________________________________ (21 CFR Part 801 Subpart D) And/Or
Over the Counter Use _________________________________________________________________________________________________________________________________________________________ (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Image /page/5/Picture/12 description: The image shows a stamp with the word "Date:" at the top. Below that, the date is listed as "2014.05.01". The time is listed as "12:59:47". Finally, the time zone is listed as "-04'00".